DAFTAR PUSTAKA

1. World Health Organization. Prevention and treatment of pre-eclampsia and eclampsia [Internet]. 2011. 4–14 p. Available from: https://www.who.int/publications/i/item/9789241548335
2. Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al. The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens. 2018;13:291–310.
3. Espinoza J, Vidaef A, Pettker C, Simhan H. Clinical Management Guidelines for Obstetrician-Gynecologists. ACOG Pract Bull. 2020;135(6):237–60.
4. Mousa A, Mandili RL, Aljahdali M, Gari S, Khaimi S, Alahdal S, et al. Maternal and Fetal Outcomes of Preeclampsia With and Without Severe Features in King Abdulaziz University Hospital, Jeddah, Saudi Arabia: A Retrospective Study. Cureus. 2022;14(11):1–12.
5. Vats K, Paul M. Study of fetal outcome in hypertensive disorders of pregnancy in a tertiary care maternity hospital of Delhi. Int J Reprod Contraception, Obstet Gynecol. 2016;5(11):3773–7.
6. Langley-Evans SC, Pearce J, Ellis S. Overweight, obesity and excessive weight gain in pregnancy as risk factors for adverse pregnancy outcomes: A narrative review. J Hum Nutr Diet. 2022;35(2):250–64.
7. World Health Organization. Drug Treatment For Severe Hypertension In Pregnancy [Internet]. Geneva. 2018. 3 p. Available from: https://www.who.int/publications/i/item/9789241550437
8. Kementerian Kesehatan Republik Indonesia. Profil Kesehatan Indonesia 2020 [Internet]. Hardhana B, Sibuea F, Widiantini W, editors. Vol. 48. Jakarta: Kementerian Kesehatan Republik Indonesia; 2021. 133–382 p. Available from: https://www.kemkes.go.id/downloads/resources/download/pusdatin/profil-kesehatan-indonesia/Profil-Kesehatan-Indonesia-Tahun-2020.pdf

9. Rolnik DL, Nicolaides KH, Poon LC. Prevention of preeclampsia with aspirin. Am J Obstet Gynecol [Internet]. 2022;226(2):S1108–19. Available from: https://doi.org/10.1016/j.ajog.2020.08.045
10. Kaldygulova L, Ukybassova T, Aimagambetova G, Gaiday A, Tussupkaliyev A. Biological Role of Folic Acid in Pregnancy and Possible Therapeutic Application for the Prevention of Preeclampsia. Biomedicines. 2023;11(2):1–15.
11. National Institutes of Health. Folate Fact Sheet for Consumers [Internet]. National Institutes of Health. 2018. p. 1–4. Available from: https://ods.od.nih.gov/factsheets/Folate-Consumer/
12. Homer CSE, Brown MA, Mangos G, Davis GK. Non-proteinuric pre-eclampsia: A novel risk indicator in women with gestational hypertension. J Hypertens. 2008;26(2):295–302.
13. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science (80-). 2005;308:1592–4.
14. Zhou Y, Damsky CH, Fisher SJ. Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype: One cause of defective endovascular invasion in this syndrome? J Clin Invest. 1997;99(9):2152–64.
15. Phipps EA, Thadhani R, Benzing T, Karumanchi SA. Pre-eclampsia: pathogenesis, novel diagnostics and therapies. Nat Rev Nephrol [Internet]. 2019;15(5):275–89. Available from: http://dx.doi.org/10.1038/s41581-019-0119-6
16. Kanasaki K, Kalluri R. The Biology of Preeclampsia Keizo. Natl Institutes Heal [Internet]. 2009;76(8):831–7. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3624763/pdf/nihms412728.pdf
17. Rana S, Lemoine E, Granger J, Karumanchi SA. Preeclampsia: Pathophysiology, Challenges, and Perspectives. Circ Res. 2019;124(7):1094–112.
18. Harmon AC, Cornelius DC, Amaral LM, Faulkner JL, Cunningham MW,

Wallace K, et al. The role of inflammation in the pathology of preeclampsia Preeclampsia: Hypertension During Pregnancy. Clin Sci [Internet]. 2017;130(6):409–19. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484393/pdf/nihms795436.pdf

19. Brosens I, Renaer M. On the pathogenesis of placental infarcts in pre-eclampsia. J Obstet Gynaecol Br Commonw. 1972;79(9):794–9.
20. Herraiz I, Llurba E, Verlohren S, Galindo A, Bartha JL, De La Calle M, et al. Update on the Diagnosis and Prognosis of Preeclampsia with the Aid of the sFlt-1/PlGF Ratio in Singleton Pregnancies. Fetal Diagn Ther. 2018;43(2):81–9.
21. Tarasevičienė V, Grybauskienė R, Mačiulevičienė R. sFlt-1, PlGF, sFlt-1/PlGF ratio and uterine artery Doppler for preeclampsia diagnostics. Med. 2016;52(6):349–53.
22. Walsh SW. Eicosanoids in preeclampsia. Prostaglandins Leukot Essent Fat Acids. 2004;70(2):223–32.
23. Walsh SW. Preeclampsia: An imbalance in placental prostacyclin and thromboxane Production. Am J Obstet Gynecol [Internet]. 1985;152(3):335–40. Available from: http://dx.doi.org/10.1016/S0002-9378(85)80223-4
24. Moncada S, Vane JR. Arachidonic Acid Metabolites and the Interactions between Platelets and Blood-Vessel Walls. N Engl J Med. 1979;300(20):1142–7.
25. Peraçoli JC, Carvalho R De, Sérgio C, Almeida H De, Costa M, Gustavo L, et al. Pre-eclampsia / Eclampsia. Rev Bras Ginecol Obs. 2019;41(5):318–32.
26. Veisani Y, Jenabi E, Delpisheh A, Khazaei S. Angiogenic factors and the risk of preeclampsia: A systematic review and meta-analysis. Int J Reprod Biomed. 2019;17(1):1–10.
27. Lamarca B, Ryan MJ, Gilbert JS, Murphy SR, Granger J. Role of cytokines in the pathophysiology of hypertension during Preeclampsia. J Chem Soc Pakistan. 2009;31(1):175–85.
28. Keiser S, Veillon EW, Parrish MR, Bennett W, Cockrell K, Ray LF. Effects

of 17-Hydroxyprogesterone on Tumor Necrosis Factor-α- Induced Hypertension During Pregnancy. Am J Hypertens [Internet]. 2009;22(10):1120–5. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3624763/pdf/nihms412728.pdf

29. LaMarca B, Speed J, Ray LF, Cockrell K, Wallukat G, Dechend R, et al. Hypertension in response to IL-6 during pregnancy: Role of AT1-receptor activation. Int J Interf Cytokine Mediat Res. 2011;3(1):65–70.
30. Aggarwal R, Jain AK, Mittal P, Kohli M, Jawanjal P, Rath G. Association of pro- and anti-inflammatory cytokines in preeclampsia. J Clin Lab Anal. 2019;33(4):1–10.
31. Jung E, Romero R, Yeo L, Gomez-Lopez N, Chaemsaithong P, Jaovisidha A, et al. The etiology of preeclampsia. Am J Obstet Gynecol [Internet]. 2022;226(2):S844–66. Available from: https://doi.org/10.1016/j.ajog.2021.11.1356
32. Wei BJ, Chen YJ, Yu L, Wu B. Periodontal Disease and Risk of Preeclampsia: A Meta-Analysis of Observational Studies. PLoS One. 2013;8(8):1–6.
33. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet [Internet]. 2020;395(10234):1417–8. Available from: http://dx.doi.org/10.1016/S0140-6736(20)30937-5
34. Rosenbloom JI, Raghuraman N, Carter EB, Kelly JC. Coronavirus disease 2019 infection and hypertensive disorders of pregnancy. Am J Obstet Gynecol [Internet]. 2021;224(6):623–4. Available from: https://doi.org/10.1016/j.ajog.2021.03.001
35. Ogunwole SM, Mwinnyaa G, Wang X, Hong X, Henderson J, Bennett WL. Preeclampsia across pregnancies and associated risk factors: Findings from a high-risk US birth Cohort. J Am Heart Assoc. 2021;10(17):1–15.
36. Tesfa E, Nibret E, Gizaw ST, Zenebe Y, Mekonnen Z, Assefa S, et al. Prevalence and determinants of hypertensive disorders of pregnancy in

Ethiopia: A systematic review and meta-analysis. PLoS One [Internet]. 2020;15:1–21. Available from: http://dx.doi.org/10.1371/journal.pone.0239048

37. Irawati, Candra. Biduati, Endang. Rahayu D. Analisis Faktor Risiko Kejadian Preekalmpsia Berat di Kabupaten Mesuji Tahun 2023. J Chem Inf Model. 2019;15(2):9–25.
38. Czeizel AE, Bánhidy F. Chronic hypertension in pregnancy. Curr Opin Obstet Gynecol. 2011;23(2):76–81.
39. Wiles K, Chappell LC, Lightstone L, Bramham K. Updates in diagnosis and management of preeclampsia in women with ckd. Clin J Am Soc Nephrol. 2020;15(9):1371–80.
40. Zhang JJ, Ma XX, Hao L, Liu LJ, Lv JC, Zhang H. A systematic review and meta-analysis of outcomes of pregnancy in CKD and CKD outcomes in pregnancy. Clin J Am Soc Nephrol. 2015;10(11):1964–78.
41. Weissgerber TL, Mudd LM. Preeclampsia and Diabetes. Curr Diab Rep. 2015;15(3):1–16.
42. Holmes VA, Young IS, Patterson CC, Maresh MJA, Pearson DWM, Walker JD, et al. The role of angiogenic and antiangiogenic factors in the second trimester in the prediction of preeclampsia in pregnant women with type 1 diabetes. Diabetes Care. 2013;36(11):3671–7.
43. Knight KM, Pressman EK, Hackney DN, Thornburg LL. Perinatal outcomes in type 2 diabetic patients compared with non-diabetic patients matched by body mass index. J Matern Neonatal Med. 2012;25(6):611–5.
44. Bartsch E, Medcalf KE, Park AL, Ray JG, Al-Rubaie ZTA, Askie LM, et al. Clinical risk factors for pre-eclampsia determined in early pregnancy: Systematic review and meta-analysis of large cohort studies. BMJ. 2016;353:1–10.
45. Clark EAS, Silver RM, Branch DW. Do antiphospholipid antibodies cause preeclampsia and HELLP syndrome? Curr Rheumatol Rep. 2007;9(3):219–25.
46. Marchetti T, de Moerloose P, Gris JC. Antiphospholipid antibodies and the

risk of severe and non-severe pre-eclampsia: The NOHA case-control study. J Thromb Haemost [Internet]. 2016;14(4):675–84. Available from: https://doi.org/10.1111/jth.13257

47. Carroll TY, Mulla MJ, Han CS, Brosens JJ, Chamley LW, Giles I, et al. Modulation of trophoblast angiogenic factor secretion by antiphospholipid antibodies is not reversed by heparin. Am J Reprod Immunol. 2011;66(4):286–96.

48. Walter IJ, Klein Haneveld MJ, Lely AT, Bloemenkamp KWM, Limper M, Kooiman J. Pregnancy outcome predictors in antiphospholipid syndrome: A systematic review and meta-analysis. Autoimmun Rev [Internet]. 2021;20(10):1–19. Available from: https://doi.org/10.1016/j.autrev.2021.102901

49. Tonasih T, Kumalasary D. Analisa Determinan yang Berhubungan dengan Preeklampsia Berat pada Ibu Hamil. J SMART Kebidanan. 2020;7(1):41.

50. Soomro S, Kumar R, Lakhan H, Shaukat F. Risk Factors for Pre-eclampsia and Eclampsia Disorders in Tertiary Care Center in Sukkur, Pakistan. Cureus. 2019;11(11):e6115.

51. Yang Y, Le Ray I, Zhu J, Zhang J, Hua J, Reilly M. Preeclampsia Prevalence, Risk Factors, and Pregnancy Outcomes in Sweden and China. JAMA Netw Open. 2021;4(5):1–14.

52. Meazaw MW, Chojenta C, Muluneh MD, Loxton D. Systematic and meta-analysis of factors associated with preeclampsia and eclampsia in sub-Saharan Africa. PLoS One [Internet]. 2020;15:1–23. Available from: http://dx.doi.org/10.1371/journal.pone.0237600

53. Andriani R, Murdiningsih M, Rahmadhani SP. Hubungan Karakteristik Ibu Dengan Kejadian Preeklampsia Pada Ibu Hamil. J 'Aisyiyah Med. 2022;7(2):137–47.

54. Maheshwari M V, Khalid N, Patel PD, Alghareeb R, Hussain A. Maternal and Neonatal Outcomes of Adolescent Pregnancy: A Narrative Review. Cureus. 2022;14(6):1–10.

55. Li F, Qin J, Zhang S, Chen L. Prevalence of hypertensive disorders in

pregnancy in China: A systematic review and meta-analysis. Pregnancy Hypertens [Internet]. 2021;24:13–21. Available from: https://doi.org/10.1016/j.preghy.2021.02.001

56. Fakhraei R, Denize K, Simon A, Sharif A, Zhu-Pawlowsky J, Dingwall-Harvey ALJ, et al. Predictors of Adverse Pregnancy Outcomes in Pregnant Women Living with Obesity: A Systematic Review. Int J Environ Res Public Health. 2022;19:1–23.
57. Macedo TCC, Montagna E, Trevisan CM, Zaia V, de Oliveira R, Barbosa CP, et al. Prevalence of preeclampsia and eclampsia in adolescent pregnancy: A systematic review and meta-analysis of 291,247 adolescents worldwide since 1969. Eur J Obstet Gynecol Reprod Biol [Internet]. 2020;248:177–86. Available from: http://europepmc.org/abstract/MED/32283429
58. Bodnar LM, Catov JM, Klebanoff MA, Ness RB, Roberts JM. Prepregnancy body mass index and the occurrence of severe hypertensive disorders of pregnancy. Epidemiology. 2007;18(2):234–9.
59. Lopez-Jaramillo P, Barajas J, Wueda-Quijano SM, Lopez-Lopez C, Felix C. Obesity and Preeclampsia: Common Pathophysiological Mechanisms. Front Physiol. 2018;9:1838.
60. Barbour LA. New concepts in insulin resistance of pregnancy and gestational diabetes: Long-term implications for mother and offspring. J Obstet Gynaecol (Lahore). 2003;23(5):545–9.
61. Carpenter MW. Gestational diabetes, pregnancy hypertension, and late vascular disease. Diabetes Care. 2007;30(2):246–50.
62. Gracia PVD, Vargas C, Sánchez J, Collantes-Cubas J. Preeclampsia: Narrative review for clinical use. Heliyon. 2023;9(3):1–11.
63. Hofmeyr GJ, Lawrie TA, Atallah ÁN, Duley L, Torloni MR. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev. 2018;(10):1–5.
64. Henderson JT, Whitlock EP, O'Connor E, Senger CA, Thompson JH, Rowland MG. Low-dose aspirin for prevention of morbidity and mortality

from preeclampsia: A systematic evidence review for the u.s. preventive services task force. Ann Intern Med. 2014;160(10):695–703.

65. Wen SW, Guo Y, Rodger M, White RR, Yang Q, Smith GN, et al. Folic Acid Supplementation in Pregnancy and the Risk of Pre-Eclampsia-A Cohort Study. PLoS One. 2016;11(2):1–11.
66. Achamrah N, Ditisheim A. Nutritional approach to preeclampsia prevention. Curr Opin Clin Nutr Metab Care. 2018;21(3):168–73.
67. Wen SW, Champagne J, Rennicks White R, Coyle D, Fraser W, Smith G, et al. Effect of folic acid supplementation in pregnancy on preeclampsia: The folic acid clinical trial study. J Pregnancy. 2013;1–9.
68. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231(25):232–5.
69. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res. 2003;110(5–6):255–8.
70. Tóth L, Muszbek L, Komáromi I. Mechanism of the irreversible inhibition of human cyclooxygenase-1 by aspirin as predicted by QM/MM calculations. J Mol Graph Model [Internet]. 2013;40:99–109. Available from: http://dx.doi.org/10.1016/j.jmgm.2012.12.013
71. Ahn TG, Hwang JY. Preeclampsia and aspirin. Obstet Gynecol Sci. 2023;66(3):120–32.
72. Konturek PC, Kania J, Burnat G, Hahn EG, Konturek SJ. Prostaglandins as mediators of COX-2 derived carcinogenesis in gastrointestinal tract. J Physiol Pharmacol. 2005;56(5):57–73.
73. Patrono C. Aspirin and human platelets: from clinical trials to acetylation of cyclooxygenase and back. Trends Pharmacol Sci. 1989;10(11):453–8.
74. Crofford LJ. COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol Suppl. 1997;49:15–9.
75. Atallah A, Lecarpentier E, Goffinet F, Doret-Dion M, Gaucherand P, Tsatsaris V. Aspirin for Prevention of Preeclampsia. Drugs. 2017;77(17):1819–31.
76. Panagodage S, Yong HEJ, Da Silva Costa F, Borg AJ, Kalionis B, Brennecke

SP, et al. Low-Dose Acetylsalicylic Acid Treatment Modulates the Production of Cytokines and Improves Trophoblast Function in an in Vitro Model of Early-Onset Preeclampsia. Am J Pathol [Internet]. 2016;186(12):3217–24. Available from: http://dx.doi.org/10.1016/j.ajpath.2016.08.010

77. Li C, Raikwar NS, Santillan MK, Santillan DA, Thomas CP. Aspirin inhibits expression of sFLT1 from human cytotrophoblasts induced by hypoxia, via cyclo-oxygenase 1. Placenta. 2015;36(4):446–53.
78. Brosens I, Pijnenborg R, Vercruysse L, Romero R. The "great Obstetrical Syndromes" are associated with disorders of deep placentation. Am J Obstet Gynecol. 2011;204(3):193–201.
79. Malah N, Hofstaetter C, Raio L, Surbek D. Effects of early aspirin therapy on utero-placental hemodynamics in patients at risk of preeclampsia. J Matern Neonatal Med [Internet]. 2022;35(12):2304–10. Available from: https://doi.org/10.1080/14767058.2020.1786048
80. Walsh SW. Low-Dose Aspirin: Treatment for the Imbalance of Increased Thromboxane and Decreased Prostacyclin in Preeclampsia. Am J Perinatol. 1989;6(2):124–32.
81. Costa FS da, Panagodage S, Brennecke S, Murthi P. 274: Low-dose aspirin improves trophoblastic function in early-onset pre-eclampsia. Am J Obstet Gynecol [Internet]. 2014;210:S145. Available from: http://dx.doi.org/10.1016/j.ajog.2013.10.307
82. Pouliot M, Serhan CN. Lipoxin A4 and aspirin-triggered-15-epi-LXA4 inhibit tumor necrosis factor-α-initiated neutrophil responses and trafficking: novel regulators of a cytokine-chemokine axis relevant to perodontal disease. J Periodontal Res. 1999;34:370–3.
83. Ariel A, Chiang N, Arita M, Petasis NA, Serhan CN. Aspirin-Triggered Lipoxin A4 and B4 Analogs Block Extracellular Signal-Regulated Kinase-Dependent TNF-α Secretion from Human T Cells. J Immunol. 2003;170(12):6266–72.
84. Loussert L, Vidal F, Parant O, Hamdi SM, Vayssiere C, Guerby P. Aspirin

for prevention of preeclampsia and fetal growth restriction. Prenat Diagn. 2020;40(5):519–27.

85. American College of Obstetricians and Gynecologists. Low-Dose Aspirin Use during Pregnancy. Am Coll Obstet Gynecol. 2018;132(1):E44–52.
86. Tolcher MC, Sangi-Haghpeykar H, Mendez-Figueroa H, Aagaard KM. Low-dose aspirin for preeclampsia prevention: efficacy by ethnicity and race. Am J Obstet Gynecol MFM [Internet]. 2020;2(4):100184. Available from: https://doi.org/10.1016/j.ajogmf.2020.100184
87. Hauspurg A, Sutton EF, Catov JM, Caritis SN. Aspirin effect on adverse pregnancy outcomes associated with stage 1 hypertension in a high-risk cohort. Hypertension. 2018;72(1):202–7.
88. Moore GS, Allshouse AA, Post AL, Galan HL, Heyborne KD. Early initiation of low-dose aspirin for reduction in preeclampsia risk in high-risk women: A secondary analysis of the MFMU High-Risk Aspirin Study. J Perinatol [Internet]. 2015;35(5):328–31. Available from: http://dx.doi.org/10.1038/jp.2014.214
89. Caritis S, Sibai B, Hauth J, Lindheimer MD, Klebanoff M, Thom E, et al. Low-Dose Aspirin to Prevent Preeclampsia in Women at High Risk. N Engl J Med. 1998;338(11):701–5.
90. Bar J, Hod M, Pardo J, Fisch B, Rabinerson D, Kaplan B, et al. Effect on fetal circulation of low-dose aspirin for prevention and treatment of pre-eclampsia and intrauterine growth restriction: Doppler flow study. Ultrasound Obstet Gynecol. 1997;9:262–5.
91. Gu W, Lin J, Hou YY, Lin N, Song MF, Zeng WJ, et al. Effects of low-dose aspirin on the prevention of preeclampsia and pregnancy outcomes: A randomized controlled trial from Shanghai, China. Eur J Obstet Gynecol Reprod Biol [Internet]. 2020;248(910):156–63. Available from: https://doi.org/10.1016/j.ejogrb.2020.03.038
92. Abdi N, Rozrokh A, Alavi A, Zare S, Vafaei H, Asadi N, et al. The effect of aspirin on preeclampsia, intrauterine growth restriction and preterm delivery among healthy pregnancies with a history of preeclampsia. J Chin Med

Assoc. 2020;83(9):852–7.

93. Odibo AO, Goetzinger KR, Odibo L, Tuuli MG. Early prediction and aspirin for prevention of pre-eclampsia (EPAPP) study: A randomized controlled trial. Ultrasound Obstet Gynecol. 2015;46(4):414–8.

94. Lin L, Huai J, Li B, Zhu Y, Juan J, Zhang M, et al. A randomized controlled trial of low-dose aspirin for the prevention of preeclampsia in women at high risk in China. Am J Obstet Gynecol [Internet]. 2022;226(2):251.e1-12. Available from: https://doi.org/10.1016/j.ajog.2021.08.004

95. Liu F, Zhao M, Wang M, Yang HL, Li L. Effect of regular oral intake of aspirin during pregnancy on pregnancy outcome of high-risk pregnancy-induced hypertension syndrome patients. Eur Rev Med Pharmacol Sci. 2016;20(23):5013–6.

96. Huai J, Lin L, Juan J, Chen J, Li B, Zhu Y, et al. Preventive effect of aspirin on preeclampsia in high-risk pregnant women with stage 1 hypertension. J Clin Hypertens (Greenwich). 2021;23(5):1060–7.

97. Grab D, Paulus WE, Erdmann M, Terinde R, Oberhoffer R, Lang D, et al. Effects of low-dose aspirin on uterine and fetal blood flow during pregnancy: results of a randomized, placebo-controlled, double-blind trial. Ultrasound Obstet Gynecol. 2000;15(1):19–27.

98. Rolnik DL, Wright D, Poon LC, O'Gorman N, Syngelaki A, de Paco Matallana C, et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med. 2017;377(7):613–22.

99. Zhou L, Wang Z, Wang L, Rastogi S. Evaluation of impacts of aspirin therapy versus placebo on preeclampsia: An observational study. Heliyon [Internet]. 2023;9(9):e19527. Available from: https://doi.org/10.1016/j.heliyon.2023.e19527

100. Scott G, Gillon TE, Pels A, von Dadelszen P, Magee LA. Guidelines—similarities and dissimilarities: a systematic review of international clinical practice guidelines for pregnancy hypertension. Am J Obstet Gynecol [Internet]. 2022;226(2):S1222–36. Available from: https://doi.org/10.1016/j.ajog.2020.08.018

101. Mendoza M, Bonacina E, Garcia-Manau P, López M, Caamiña S, Vives À, et al. Aspirin Discontinuation at 24 to 28 Weeks' Gestation in Pregnancies at High Risk of Preterm Preeclampsia: A Randomized Clinical Trial. Jama. 2023;329(7):542–50.
102. Perneby C, Vahter M, Åkesson A, Bremme K, Hjemdahl P. Thromboxane metabolite excretion during pregnancy - Influence of preeclampsia and aspirin treatment. Thromb Res [Internet]. 2011;127(6):605–6. Available from: http://dx.doi.org/10.1016/j.thromres.2011.01.005
103. Vieillefosse S, Guibourdenche J, Atallah A, Haddad B, Fournier T, Tsatsaris V, et al. Facteurs prédictifs et pronostiques de la prééclampsie : intérêt du dosage du PlGF et du sFLT-1. J Gynecol Obstet Biol la Reprod [Internet]. 2016;45(9):999–1008. Available from: http://dx.doi.org/10.1016/j.jgyn.2016.02.006
104. Wu C, Li L, Zhang J, Song Y. Efficacy and safety of low-dose aspirin combined with low-molecular-weight heparin in treatment of preeclampsia: a meta-analysis and systematic review. Arch Med Sci. 2022;18(6):1525–34.
105. Chang L, Liu Y, Zhang X, Shi Z, Ren D, Li X, et al. The clinical effect of aspirin combined with low-molecular-weight heparin in the treatment of severe preeclampsia and the combination's effect on pregnancy outcomes. Am J Transl Res. 2021;13(8):9113–21.
106. Trust N. Guideline for the use of Low Dose Aspirin in Pregnancy [Internet]. Hull University Teacing Hospital. 2022. p. 1–6. Available from: https://www.hey.nhs.uk/patient-leaflet/aspirin-in-pregnancy/
107. FDA. FDA recommends avoiding use of NSAIDs in pregnancy at 20 weeks or later because they can result in low amniotic fluid NSAIDs may cause rare kidney problems in unborn babies. FDA Drug Saf Commun [Internet]. 2020; Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-avoiding-use-nsaids-pregnancy-20-weeks-or-later-because-they-can-result-low-amniotic
108. Wright AJA, Dainty JR, Finglas PM. Folic acid metabolism in human subjects revisited: Potential implications for proposed mandatory folic acid

fortification in the UK. Br J Nutr. 2007;98(4):667–75.

109. Steinberg SE, Campbell CL, Hillman RS. Kinetics of the normal folate enterohepatic cycle. J Clin Invest. 1979;64(1):83–8.

110. Smulders YM, Stehouwer CDA. Folate metabolism and cardiovascular disease. Semin Vasc Med. 2005;5(2):87–97.

111. Ebara S. Nutritional role of folate. Congenit Anom (Kyoto). 2017;57(5):138–41.

112. Thaler CJ. Folate metabolism and human reproduction. Geburtshilfe Frauenheilkd. 2014;74(9):845–51.

113. Cetin I, Berti C, Calabrese S. Role of micronutrients in the periconceptional period. Hum Reprod Update. 2009;16(1):80–95.

114. Kalhan SC. One-carbon metabolism, fetal growth and long-term consequences. Nestle Nutr Inst Workshop Ser. 2013;74(216):127–38.

115. Barbour RS, Macleod M, Mires G, Anderson AS. Uptake of folic acid supplements before and during pregnancy: Focus group analysis of women's views and experiences. J Hum Nutr Diet. 2012;25(2):140–7.

116. American College of Obstetricians and Gynecologists. Nutrition During Pregnancy [Internet]. ACOG for Patient. 2023. Available from: https://www.acog.org/womens-health/faqs/nutrition-during-pregnancy

117. Dwyer ER, Filion KB, MacFarlane AJ, Platt RW, Mehrabadi A. Who should consume high-dose folic acid supplements before and during early pregnancy for the prevention of neural tube defects? BMJ [Internet]. 2022;377:e067728. Available from: http://www.bmj.com/content/377/bmj-2021-067728.abstract

118. Merrell B, McMurry J. Folic Acid. In: StatPearls [Internet] [Internet]. StatPearls Publishing, Treasure Island (FL); 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554487/

119. Antoniades C, Shirodaria C, Warrick N, Cai S, De Bono J, Lee J, et al. 5-Methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: Effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase

coupling. Circulation. 2006;114(11):1193–201.

120. Mignini LE, Latthe PM, Villar J, Kilby MD, Carroli G, Khan KS. Mapping the theories of preeclampsia: The role of homocysteine. Obstet Gynecol. 2005;105(2):411–25.
121. Guo Y, Smith GN, Wen SW, Walker MC. Folate metabolism and preeclampsia. Fetal Matern Med Rev. 2012;23(2):131–55.
122. Kamudhamas A, Pang L, Smith SD, Sadovsky Y, Nelson DM. Homocysteine thiolactone induces apoptosis in cultured human trophoblasts: A mechanism for homocysteine-mediated placental dysfunction? Am J Obstet Gynecol. 2004;191(2):563–71.
123. Di Simone N, Maggiano N, Caliandro D, Riccardi P, Evangelista A, Carducci B, et al. Homocysteine induces trophoblast cell death with apoptotic features. Biol Reprod. 2003;69(4):1129–34.
124. Wen SW, White RR, Rybak N, Gaudet LM, Robson S, Hague W, et al. Effect of high dose folic acid supplementation in pregnancy on pre-eclampsia (FACT): double blind, phase III, randomised controlled, international, multicentre trial. BMJ. 2018;362(1–20):k3478.
125. Corsi DJ, Gaudet LM, El-Chaar D, White RR, Rybak N, Harvey A, et al. Effect of high-dose folic acid supplementation on the prevention of preeclampsia in twin pregnancy. J Matern Neonatal Med [Internet]. 2022;35(3):503–8. Available from: https://doi.org/10.1080/14767058.2020.1725882
126. World Health Organization. Serum and red blood cell folate concentrations for assessing folate status in populations. Vitam Miner Nutr Inf Syst [Internet]. 2015;1–7. Available from: https://www.who.int/publications/i/item/WHO-NMH-NHD-EPG-15.01
127. Yusuf A. Pengaruh Asupan Asam Folat Serum Maternal terhadap Kejadian Preeklampsia Berat. J Agromed Unila [Internet]. 2015;2(3):272–7. Available from: http://repository2.unw.ac.id/752/
128. Emeksiz HC, Serdaroglu A, Biberoglu G, Gulbahar O, Arhan E, Cansu A, et al. Assessment of atherosclerosis risk due to the homocysteine-asymmetric

dimethylarginine-nitric oxide cascade in children taking antiepileptic drugs. Seizure. 2013;22(2):124–7.

129. Argyridis S. Folic acid in pregnancy. Obstet Gynaecol Reprod Med. 2019;29(4):118–20.
130. Williams PJ, Bulmer JN, Innes BA, Pipkin FB. Possible roles for folic acid in the regulation of trophoblast invasion and placental development in normal early human pregnancy. Biol Reprod. 2011;84(6):1148–53.
131. Impellizzeri FM, Bizzini M. Systematic review and meta-analysis: A primer. Int J Sports Phys Ther. 2012;7(5):493–503.
132. Ebrashy A, Ibrahim M, Marzook A, Yousef D. Usefulness of aspirin therapy in high-risk pregnant women with abnormal uterine artery Doppler ultrasound at 14-16 weeks pregnancy: randomized controlled clinical trial. Croat Med J. 2005 Oct;46(5):826–31.
133. Cong J, Pu D, Tan R, Ge X, Zhu W, Shen CE, et al. Association between Folic Acid Supplementation and Hypertensive Disorder Complicating Pregnancy in Jiangsu Province: A Cross-Sectional Study. Evidence-based Complement Altern Med. 2022;1–9.